Shopping Cart 0
Cart Subtotal
AED 0

Pancreatic Cancer - Pipeline Review, H1 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 9175

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 18350

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 27525

Details

Pancreatic Cancer -Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer -Pipeline Review, H1 2018, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape.

Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood clots. Predisposing factors include age, gender, smoking, diabetes and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pancreatic Cancer -Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatic Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 19, 146, 138, 2, 11, 289, 35 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 18, 11, 2, 1, 48 and 7 molecules, respectively.

Pancreatic Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

-The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Cancer (Oncology).

-The pipeline guide reviews pipeline therapeutics for Pancreatic Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

-The pipeline guide reviews key companies involved in Pancreatic Cancer (Oncology) therapeutics and enlists all their major and minor projects.

-The pipeline guide evaluates Pancreatic Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

-The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatic Cancer (Oncology)

Reasons to buy

-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

-Find and recognize significant and varied types of therapeutics under development for Pancreatic Cancer (Oncology).

-Classify potential new clients or partners in the target demographic.

-Develop tactical initiatives by understanding the focus areas of leading companies.

-Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.

-Formulate corrective measures for pipeline projects by understanding Pancreatic Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

-Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.<

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 14

Pancreatic Cancer -Overview 15

Pancreatic Cancer -Therapeutics Development 16

Pancreatic Cancer -Therapeutics Assessment 89

Pancreatic Cancer -Companies Involved in Therapeutics Development 127

Pancreatic Cancer -Drug Profiles 268

Pancreatic Cancer -Dormant Projects 2392

Pancreatic Cancer -Discontinued Products 2418

Pancreatic Cancer -Product Development Milestones 2424

Appendix 2438


List Of Figure

List of Figures

Number of Products under Development for Pancreatic Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018


List Of Table

List of Tables

Number of Products under Development for Pancreatic Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..8), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..9), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..10), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..11), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..12), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..13), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..14), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..15), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..16), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..17), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..18), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..19), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..20), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..21), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..22), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Products under Development by Companies, H1 2018 (Contd..8), H1 2018

Products under Development by Companies, H1 2018 (Contd..9), H1 2018

Products under Development by Companies, H1 2018 (Contd..10), H1 2018

Products under Development by Companies, H1 2018 (Contd..11), H1 2018

Products under Development by Companies, H1 2018 (Contd..12), H1 2018

Products under Development by Companies, H1 2018 (Contd..13), H1 2018

Products under Development by Companies, H1 2018 (Contd..14), H1 2018

Products under Development by Companies, H1 2018 (Contd..15), H1 2018

Products under Development by Companies, H1 2018 (Contd..16), H1 2018

Products under Development by Companies, H1 2018 (Contd..17), H1 2018

Products under Development by Companies, H1 2018 (Contd..18), H1 2018

Products under Development by Companies, H1 2018 (Contd..19), H1 2018

Products under Development by Companies, H1 2018 (Contd..20), H1 2018

Products under Development by Companies, H1 2018 (Contd..21), H1 2018

Products under Development by Companies, H1 2018 (Contd..22), H1 2018

Products under Development by Companies, H1 2018 (Contd..23), H1 2018

Products under Development by Companies, H1 2018 (Contd..24), H1 2018

Products under Development by Companies, H1 2018 (Contd..25), H1 2018

Products under Development by Companies, H1 2018 (Contd..26), H1 2018

Products under Development by Companies, H1 2018 (Contd..27), H1 2018

Products under Development by Companies, H1 2018 (Contd..28), H1 2018

Products under Development by Companies, H1 2018 (Contd..29), H1 2018

Products under Development by Companies, H1 2018 (Contd..30), H1 2018

Products under Development by Companies, H1 2018 (Contd..31), H1 2018

Products under Development by Companies, H1 2018 (Contd..32), H1 2018

Products under Development by Companies, H1 2018 (Contd..33), H1 2018

Products under Development by Companies, H1 2018 (Contd..34), H1 2018

Products under Development by Companies, H1 2018 (Contd..35), H1 2018

Products under Development by Companies, H1 2018 (Contd..36), H1 2018

Products under Development by Universities/Institutes, H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..2), H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..3), H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..4), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Pancreatic Cancer Therapeutic Products under Development, Key Players in Pancreatic Cancer Therapeutics, Pancreatic Cancer Pipeline Overview, Pancreatic Cancer Pipeline, Pancreatic Cancer Pipeline Assessment


Companies

3-V Biosciences Inc

4P-Pharma SAS

4SC AG

AB Science SA

AbbVie Inc

AbGenomics International Inc

Ability Pharmaceuticals SL

Aclaris Therapeutics Inc

Actuate Therapeutics Inc

Adamed Sp z oo

Aduro BioTech Inc

Advantagene Inc

AGV Discovery SAS

AIMM Therapeutics BV

Alissa Pharma

Alligator Bioscience AB

Allinky Biopharma

Altor BioScience Corp

Ambrx Inc

amcure GmbH

Amgen Inc

Amplia Therapeutics Pty Ltd

Anavex Life Sciences Corp

Andarix Pharmaceuticals Inc

ANP Technologies Inc

AntiCancer Inc

APEIRON Biologics AG

Apexigen Inc

Aphios Corp

Aposense Ltd

ARMO Biosciences Inc

ArQule Inc

Array BioPharma Inc

Asana BioSciences LLC

Astellas Pharma Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

AVEO Pharmaceuticals Inc

Axcentua Pharmaceuticals AB

Basilea Pharmaceutica Ltd

Bavarian Nordic A/S

Bayer AG

BeiGene Ltd

Bellicum Pharmaceuticals Inc

Berg LLC

BerGenBio ASA

Bexion Pharmaceuticals LLC

BeyondSpring Pharmaceuticals Inc

Bio-Path Holdings Inc

BioAtla LLC

BioLineRx Ltd

BioMoti Ltd

Biomunex Pharmaceuticals

Bionomics Ltd

BioNTech AG

Biothera Pharmaceutical Inc

Biouniversa srl

BLR Bio LLC

Boehringer Ingelheim GmbH

Boston Biomedical Inc

BriaCell Therapeutics Corp

Bristol-Myers Squibb Co

Calithera Biosciences Inc

Cancer Prevention Pharmaceuticals Inc

Cantargia AB

Cantex Pharmaceuticals Inc

CARsgen Therapeutics Ltd

CBT Pharmaceuticals Inc

CCRP Therapeutics GmbH

Celgene Corp

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Celleron Therapeutics Ltd

Cellular Biomedicine Group Inc

Celprogen Inc

Celyad SA

Centrose LLC

Chem-Master International Inc

ChemoCentryx Inc

Chugai Pharmaceutical Co Ltd

Clovis Oncology Inc

COARE Biotechnology Inc

Codiak BioSciences Inc

Concordia International Corp

Corcept Therapeutics Inc

Cotinga Pharmaceuticals Inc

CPL Biologicals Pvt Ltd

CrystalGenomics Inc

CTI BioPharma Corp

Cyclacel Pharmaceuticals Inc

CytImmune Sciences Inc

Cytori Therapeutics Inc

CyTuVax BV

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

DEKK-TEC Inc

Denceptor Therapeutics Ltd

Diffusion Pharmaceuticals Inc

Eleison Pharmaceuticals LLC

Eli Lilly and Co

Endor Nanotechnologies SL

Ensol Biosciences Inc

Enterome Bioscience SA

Erytech Pharma SA

Esperance Pharmaceuticals Inc

Etubics Corp

Exelixis Inc

F. Hoffmann-La Roche Ltd

Faron Pharmaceuticals Oy

Felicitex Therapeutics Inc

FibroGen Inc

Formation Biologics Inc

Formosa Laboratories Inc

Forty Seven Inc

Fountain Biopharma Inc

Fujifilm Holdings Corporation

Fusion Antibodies Ltd

Galera Therapeutics Inc

GamaMabs Pharma SA

Geistlich Pharma AG

Genelux Corp

Genentech Inc

Genisphere LLC

Genmab A/S

Genoscience Pharma

Gilead Sciences Inc

GlaxoSmithKline Plc

GlycoMimetics Inc

Glycotope GmbH

Golden Biotechnology Corp

GW Pharmaceuticals Plc

Halozyme Therapeutics Inc

Heidelberg Pharma AG

Helix BioPharma Corp

Hemispherx Biopharma Inc

Horizon Pharma Plc

Icell Kealex Therapeutics LLC

Idera Pharmaceuticals Inc

Igenica Biotherapeutics Inc

Ignyta Inc

Immix BioPharma Inc

Immodulon Therapeutics Ltd

Immune System Key Ltd

Immunitor Inc

Immunomedics Inc

Immunotope Inc

Immunovo BV

Immupharma Plc

Incyte Corp

Inflection Biosciences Ltd

Innopharmax Inc

Innovation Pharmaceuticals Inc

Inovio Pharmaceuticals Inc

InteRNA Technologies BV

Intezyne Technologies Inc

Inventiva

InvivoGen Therapeutics

Io Therapeutics Inc

Iovance Biotherapeutics Inc

Ipsen SA

ISU ABXIS Co Ltd

Jasco Pharmaceuticals LLC

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Juno Therapeutics Inc

Kalyra Pharmaceuticals Inc

Karcinolys SAS

Karyopharm Therapeutics Inc

Kazia Therapeutics Ltd

Keystone Nano Inc

Komipharm International Co Ltd

Kringle Pharma Inc

Kuhnil Pharmaceutical Co Ltd

Kura Oncology Inc

Kyowa Hakko Kirin Co Ltd

Lead Discovery Center GmbH

LIfT BioSciences Ltd

Lixte Biotechnology Holdings Inc

Loxo Oncology Inc

Lymphocyte Activation Technologies SA

MabVax Therapeutics Holdings Inc

Machavert Pharmaceuticals LLC

MacroGenics Inc

MaxiVAX SA

Meabco AS

Mebiopharm Co Ltd

MediaPharma SRL

Medicenna Therapeutics Corp

MediciNova Inc

MedImmune LLC

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Merus NV

MetaMax Ltd

Millennium Pharmaceuticals Inc

Mitsubishi Tanabe Pharma Corp

Moderna Therapeutics Inc

Molecular Partners AG

Molecular Targeting Technologies Inc

Molecular Templates Inc

Moleculin Biotech LLC

Monopar Therapeutics Inc

Morphotek Inc

Mycenax Biotech Inc

NanoCarrier Co Ltd

NanoVector Inc

NantKwest Inc

Nascent Biotech Inc

Natco Pharma Ltd

NatureWise Biotech & Medicals Corp

NBE-Therapeutics AG

Nektar Therapeutics

Nerviano Medical Sciences Srl

NewLink Genetics Corp

NormOxys Inc

Northern Biologics Inc

Northwest Biotherapeutics Inc

Novartis AG

Noxxon Pharma AG

NuCana Plc

OBI Pharma Inc

Omeros Corp

Oncodesign SA

Oncology Research International Ltd

Oncolytics Biotech Inc

Oncomatryx Biopharma SL

OncoMed Pharmaceuticals Inc

OncoTherapy Science Inc

Oncovir Inc

Ono Pharmaceutical Co Ltd

Opsona Therapeutics Ltd

Optimum Therapeutics LLC

Oribase Pharma

Oryx GmbH & Co KG

OSE Immunotherapeutics

Oxford BioTherapeutics Ltd

Patrys Ltd

Pfizer Inc

Pharma Mar SA

PharmAbcine Inc

PharmaCyte Biotech Inc

Pharmedartis GmbH

Phenex Pharmaceuticals AG

Phoenix Biotechnology Inc

Plexxikon Inc

Polaris Pharmaceuticals Inc

POP Biotechnologies Inc

Precision Biologics Inc

Prescient Therapeutics Ltd

Propanc Biopharma Inc

Provectus Biopharmaceuticals Inc

Purdue Pharma LP

Puretech Health plc

Quest PharmaTech Inc

Quimatryx SL

Rafael Pharmaceuticals Inc

RedHill Biopharma Ltd

Rexahn Pharmaceuticals Inc

Rhizen Pharmaceuticals SA

RS Research

Sagetis Biotech SL

Samumed LLC

Samyang Holdings Corp

Sanofi

Sareum Holdings Plc

SATT North SAS

Scancell Holdings Plc

Seattle Genetics Inc

Selecta Biosciences Inc

SELLAS Life Sciences Group Inc

Siamab Therapeutics Inc

Sichuan Kelun Pharmaceutical Co Ltd

Sierra Oncology Inc

SignalChem Lifesciences Corp

SignPath Pharma Inc

SilaGene Inc

Silenseed Ltd

Sillajen Biotherapeutics

Sino Biopharmaceutical Ltd

Soricimed Biopharma Inc

Spring Bank Pharmaceuticals Inc

Strongbridge Biopharma plc

Sumitomo Dainippon Pharma Co Ltd

Sun BioPharma Inc

Sun Pharma Advanced Research Company Ltd

Swedish Orphan Biovitrum AB

Symic Biomedical Inc

Symphogen A/S

SynCore Biotechnology Co Ltd

Syndax Pharmaceuticals Inc

Synergys Biotherapeutics Inc

Synovo GmbH

Taiho Pharmaceutical Co Ltd

Takara Bio Inc

Takeda Pharmaceutical Co Ltd

Takis Srl

Targovax ASA

Tarveda Therapeutics Inc

TCR2 Therapeutics Inc

tella Inc

Tesaro Inc

Tiziana Life Sciences Plc

Tocagen Inc

Transcriptogen Ltd

Transgene SA

Trovagene Inc

Tyg Oncology Ltd

Tyme Technologies Inc

Tyrogenex Inc

UbiVac LLC

ValiRx Plc

VasGene Therapeutics Inc

Vault Pharma Inc

Vaxeal Holding SA

Vaximm AG

Vaxon Biotech

VCN Biosciences SL

Vect-Horus SAS

Verastem Inc

VG Life Sciences Inc

Vicus Therapeutics LLC

Viralytics Ltd

Virobay Inc

ViroStatics srl

XBiotech Inc

XuanZhu Pharma Co Ltd

Zeria Pharmaceutical Co Ltd

Company Profile

Company Profile Title

Pancreatic Cancer -Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer -Pipeline Review, H1 2018, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape.

Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood clots. Predisposing factors include age, gender, smoking, diabetes and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pancreatic Cancer -Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pancreatic Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 19, 146, 138, 2, 11, 289, 35 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 18, 11, 2, 1, 48 and 7 molecules, respectively.

Pancreatic Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

-The pipeline guide provides a snapshot of the global therapeutic landscape of Pancreatic Cancer (Oncology).

-The pipeline guide reviews pipeline therapeutics for Pancreatic Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

-The pipeline guide reviews key companies involved in Pancreatic Cancer (Oncology) therapeutics and enlists all their major and minor projects.

-The pipeline guide evaluates Pancreatic Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

-The pipeline guide reviews latest news related to pipeline therapeutics for Pancreatic Cancer (Oncology)

Reasons to buy

-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

-Find and recognize significant and varied types of therapeutics under development for Pancreatic Cancer (Oncology).

-Classify potential new clients or partners in the target demographic.

-Develop tactical initiatives by understanding the focus areas of leading companies.

-Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.

-Formulate corrective measures for pipeline projects by understanding Pancreatic Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

-Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.<

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 14

Pancreatic Cancer -Overview 15

Pancreatic Cancer -Therapeutics Development 16

Pancreatic Cancer -Therapeutics Assessment 89

Pancreatic Cancer -Companies Involved in Therapeutics Development 127

Pancreatic Cancer -Drug Profiles 268

Pancreatic Cancer -Dormant Projects 2392

Pancreatic Cancer -Discontinued Products 2418

Pancreatic Cancer -Product Development Milestones 2424

Appendix 2438


List Of Figure

List of Figures

Number of Products under Development for Pancreatic Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018


List Of Table

List of Tables

Number of Products under Development for Pancreatic Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..8), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..9), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..10), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..11), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..12), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..13), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..14), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..15), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..16), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..17), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..18), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..19), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..20), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..21), H1 2018

Number of Products under Development by Companies, H1 2018 (Contd..22), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Number of Products under Development by Universities/Institutes, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018 (Contd..1), H1 2018

Products under Development by Companies, H1 2018 (Contd..2), H1 2018

Products under Development by Companies, H1 2018 (Contd..3), H1 2018

Products under Development by Companies, H1 2018 (Contd..4), H1 2018

Products under Development by Companies, H1 2018 (Contd..5), H1 2018

Products under Development by Companies, H1 2018 (Contd..6), H1 2018

Products under Development by Companies, H1 2018 (Contd..7), H1 2018

Products under Development by Companies, H1 2018 (Contd..8), H1 2018

Products under Development by Companies, H1 2018 (Contd..9), H1 2018

Products under Development by Companies, H1 2018 (Contd..10), H1 2018

Products under Development by Companies, H1 2018 (Contd..11), H1 2018

Products under Development by Companies, H1 2018 (Contd..12), H1 2018

Products under Development by Companies, H1 2018 (Contd..13), H1 2018

Products under Development by Companies, H1 2018 (Contd..14), H1 2018

Products under Development by Companies, H1 2018 (Contd..15), H1 2018

Products under Development by Companies, H1 2018 (Contd..16), H1 2018

Products under Development by Companies, H1 2018 (Contd..17), H1 2018

Products under Development by Companies, H1 2018 (Contd..18), H1 2018

Products under Development by Companies, H1 2018 (Contd..19), H1 2018

Products under Development by Companies, H1 2018 (Contd..20), H1 2018

Products under Development by Companies, H1 2018 (Contd..21), H1 2018

Products under Development by Companies, H1 2018 (Contd..22), H1 2018

Products under Development by Companies, H1 2018 (Contd..23), H1 2018

Products under Development by Companies, H1 2018 (Contd..24), H1 2018

Products under Development by Companies, H1 2018 (Contd..25), H1 2018

Products under Development by Companies, H1 2018 (Contd..26), H1 2018

Products under Development by Companies, H1 2018 (Contd..27), H1 2018

Products under Development by Companies, H1 2018 (Contd..28), H1 2018

Products under Development by Companies, H1 2018 (Contd..29), H1 2018

Products under Development by Companies, H1 2018 (Contd..30), H1 2018

Products under Development by Companies, H1 2018 (Contd..31), H1 2018

Products under Development by Companies, H1 2018 (Contd..32), H1 2018

Products under Development by Companies, H1 2018 (Contd..33), H1 2018

Products under Development by Companies, H1 2018 (Contd..34), H1 2018

Products under Development by Companies, H1 2018 (Contd..35), H1 2018

Products under Development by Companies, H1 2018 (Contd..36), H1 2018

Products under Development by Universities/Institutes, H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..2), H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..3), H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..4), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..2), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..3), H1 2018

Number of Products by Stage and Target, H1 2018 (Contd..4), H1 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Pancreatic Cancer Therapeutic Products under Development, Key Players in Pancreatic Cancer Therapeutics, Pancreatic Cancer Pipeline Overview, Pancreatic Cancer Pipeline, Pancreatic Cancer Pipeline Assessment


Companies

3-V Biosciences Inc

4P-Pharma SAS

4SC AG

AB Science SA

AbbVie Inc

AbGenomics International Inc

Ability Pharmaceuticals SL

Aclaris Therapeutics Inc

Actuate Therapeutics Inc

Adamed Sp z oo

Aduro BioTech Inc

Advantagene Inc

AGV Discovery SAS

AIMM Therapeutics BV

Alissa Pharma

Alligator Bioscience AB

Allinky Biopharma

Altor BioScience Corp

Ambrx Inc

amcure GmbH

Amgen Inc

Amplia Therapeutics Pty Ltd

Anavex Life Sciences Corp

Andarix Pharmaceuticals Inc

ANP Technologies Inc

AntiCancer Inc

APEIRON Biologics AG

Apexigen Inc

Aphios Corp

Aposense Ltd

ARMO Biosciences Inc

ArQule Inc

Array BioPharma Inc

Asana BioSciences LLC

Astellas Pharma Inc

AstraZeneca Plc

Aurigene Discovery Technologies Ltd

AVEO Pharmaceuticals Inc

Axcentua Pharmaceuticals AB

Basilea Pharmaceutica Ltd

Bavarian Nordic A/S

Bayer AG

BeiGene Ltd

Bellicum Pharmaceuticals Inc

Berg LLC

BerGenBio ASA

Bexion Pharmaceuticals LLC

BeyondSpring Pharmaceuticals Inc

Bio-Path Holdings Inc

BioAtla LLC

BioLineRx Ltd

BioMoti Ltd

Biomunex Pharmaceuticals

Bionomics Ltd

BioNTech AG

Biothera Pharmaceutical Inc

Biouniversa srl

BLR Bio LLC

Boehringer Ingelheim GmbH

Boston Biomedical Inc

BriaCell Therapeutics Corp

Bristol-Myers Squibb Co

Calithera Biosciences Inc

Cancer Prevention Pharmaceuticals Inc

Cantargia AB

Cantex Pharmaceuticals Inc

CARsgen Therapeutics Ltd

CBT Pharmaceuticals Inc

CCRP Therapeutics GmbH

Celgene Corp

Celldex Therapeutics Inc

Cellectar Biosciences Inc

Celleron Therapeutics Ltd

Cellular Biomedicine Group Inc

Celprogen Inc

Celyad SA

Centrose LLC

Chem-Master International Inc

ChemoCentryx Inc

Chugai Pharmaceutical Co Ltd

Clovis Oncology Inc

COARE Biotechnology Inc

Codiak BioSciences Inc

Concordia International Corp

Corcept Therapeutics Inc

Cotinga Pharmaceuticals Inc

CPL Biologicals Pvt Ltd

CrystalGenomics Inc

CTI BioPharma Corp

Cyclacel Pharmaceuticals Inc

CytImmune Sciences Inc

Cytori Therapeutics Inc

CyTuVax BV

Daewoong Pharmaceutical Co Ltd

Daiichi Sankyo Co Ltd

DEKK-TEC Inc

Denceptor Therapeutics Ltd

Diffusion Pharmaceuticals Inc

Eleison Pharmaceuticals LLC

Eli Lilly and Co

Endor Nanotechnologies SL

Ensol Biosciences Inc

Enterome Bioscience SA

Erytech Pharma SA

Esperance Pharmaceuticals Inc

Etubics Corp

Exelixis Inc

F. Hoffmann-La Roche Ltd

Faron Pharmaceuticals Oy

Felicitex Therapeutics Inc

FibroGen Inc

Formation Biologics Inc

Formosa Laboratories Inc

Forty Seven Inc

Fountain Biopharma Inc

Fujifilm Holdings Corporation

Fusion Antibodies Ltd

Galera Therapeutics Inc

GamaMabs Pharma SA

Geistlich Pharma AG

Genelux Corp

Genentech Inc

Genisphere LLC

Genmab A/S

Genoscience Pharma

Gilead Sciences Inc

GlaxoSmithKline Plc

GlycoMimetics Inc

Glycotope GmbH

Golden Biotechnology Corp

GW Pharmaceuticals Plc

Halozyme Therapeutics Inc

Heidelberg Pharma AG

Helix BioPharma Corp

Hemispherx Biopharma Inc

Horizon Pharma Plc

Icell Kealex Therapeutics LLC

Idera Pharmaceuticals Inc

Igenica Biotherapeutics Inc

Ignyta Inc

Immix BioPharma Inc

Immodulon Therapeutics Ltd

Immune System Key Ltd

Immunitor Inc

Immunomedics Inc

Immunotope Inc

Immunovo BV

Immupharma Plc

Incyte Corp

Inflection Biosciences Ltd

Innopharmax Inc

Innovation Pharmaceuticals Inc

Inovio Pharmaceuticals Inc

InteRNA Technologies BV

Intezyne Technologies Inc

Inventiva

InvivoGen Therapeutics

Io Therapeutics Inc

Iovance Biotherapeutics Inc

Ipsen SA

ISU ABXIS Co Ltd

Jasco Pharmaceuticals LLC

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Juno Therapeutics Inc

Kalyra Pharmaceuticals Inc

Karcinolys SAS

Karyopharm Therapeutics Inc

Kazia Therapeutics Ltd

Keystone Nano Inc

Komipharm International Co Ltd

Kringle Pharma Inc

Kuhnil Pharmaceutical Co Ltd

Kura Oncology Inc

Kyowa Hakko Kirin Co Ltd

Lead Discovery Center GmbH

LIfT BioSciences Ltd

Lixte Biotechnology Holdings Inc

Loxo Oncology Inc

Lymphocyte Activation Technologies SA

MabVax Therapeutics Holdings Inc

Machavert Pharmaceuticals LLC

MacroGenics Inc

MaxiVAX SA

Meabco AS

Mebiopharm Co Ltd

MediaPharma SRL

Medicenna Therapeutics Corp

MediciNova Inc

MedImmune LLC

Merck & Co Inc

Merck KGaA

Merrimack Pharmaceuticals Inc

Merus NV

MetaMax Ltd

Millennium Pharmaceuticals Inc

Mitsubishi Tanabe Pharma Corp

Moderna Therapeutics Inc

Molecular Partners AG

Molecular Targeting Technologies Inc

Molecular Templates Inc

Moleculin Biotech LLC

Monopar Therapeutics Inc

Morphotek Inc

Mycenax Biotech Inc

NanoCarrier Co Ltd

NanoVector Inc

NantKwest Inc

Nascent Biotech Inc

Natco Pharma Ltd

NatureWise Biotech & Medicals Corp

NBE-Therapeutics AG

Nektar Therapeutics

Nerviano Medical Sciences Srl

NewLink Genetics Corp

NormOxys Inc

Northern Biologics Inc

Northwest Biotherapeutics Inc

Novartis AG

Noxxon Pharma AG

NuCana Plc

OBI Pharma Inc

Omeros Corp

Oncodesign SA

Oncology Research International Ltd

Oncolytics Biotech Inc

Oncomatryx Biopharma SL

OncoMed Pharmaceuticals Inc

OncoTherapy Science Inc

Oncovir Inc

Ono Pharmaceutical Co Ltd

Opsona Therapeutics Ltd

Optimum Therapeutics LLC

Oribase Pharma

Oryx GmbH & Co KG

OSE Immunotherapeutics

Oxford BioTherapeutics Ltd

Patrys Ltd

Pfizer Inc

Pharma Mar SA

PharmAbcine Inc

PharmaCyte Biotech Inc

Pharmedartis GmbH

Phenex Pharmaceuticals AG

Phoenix Biotechnology Inc

Plexxikon Inc

Polaris Pharmaceuticals Inc

POP Biotechnologies Inc

Precision Biologics Inc

Prescient Therapeutics Ltd

Propanc Biopharma Inc

Provectus Biopharmaceuticals Inc

Purdue Pharma LP

Puretech Health plc

Quest PharmaTech Inc

Quimatryx SL

Rafael Pharmaceuticals Inc

RedHill Biopharma Ltd

Rexahn Pharmaceuticals Inc

Rhizen Pharmaceuticals SA

RS Research

Sagetis Biotech SL

Samumed LLC

Samyang Holdings Corp

Sanofi

Sareum Holdings Plc

SATT North SAS

Scancell Holdings Plc

Seattle Genetics Inc

Selecta Biosciences Inc

SELLAS Life Sciences Group Inc

Siamab Therapeutics Inc

Sichuan Kelun Pharmaceutical Co Ltd

Sierra Oncology Inc

SignalChem Lifesciences Corp

SignPath Pharma Inc

SilaGene Inc

Silenseed Ltd

Sillajen Biotherapeutics

Sino Biopharmaceutical Ltd

Soricimed Biopharma Inc

Spring Bank Pharmaceuticals Inc

Strongbridge Biopharma plc

Sumitomo Dainippon Pharma Co Ltd

Sun BioPharma Inc

Sun Pharma Advanced Research Company Ltd

Swedish Orphan Biovitrum AB

Symic Biomedical Inc

Symphogen A/S

SynCore Biotechnology Co Ltd

Syndax Pharmaceuticals Inc

Synergys Biotherapeutics Inc

Synovo GmbH

Taiho Pharmaceutical Co Ltd

Takara Bio Inc

Takeda Pharmaceutical Co Ltd

Takis Srl

Targovax ASA

Tarveda Therapeutics Inc

TCR2 Therapeutics Inc

tella Inc

Tesaro Inc

Tiziana Life Sciences Plc

Tocagen Inc

Transcriptogen Ltd

Transgene SA

Trovagene Inc

Tyg Oncology Ltd

Tyme Technologies Inc

Tyrogenex Inc

UbiVac LLC

ValiRx Plc

VasGene Therapeutics Inc

Vault Pharma Inc

Vaxeal Holding SA

Vaximm AG

Vaxon Biotech

VCN Biosciences SL

Vect-Horus SAS

Verastem Inc

VG Life Sciences Inc

Vicus Therapeutics LLC

Viralytics Ltd

Virobay Inc

ViroStatics srl

XBiotech Inc

XuanZhu Pharma Co Ltd

Zeria Pharmaceutical Co Ltd